ISRCTN38691965已完成不适用
ewcastle Twin Antenatal Programme (TAP) a randomised controlled trial (RCT) Study
HS R&D Regional Programme Register - Department of Health (UK)0 个研究点目标入组 0 人开始时间: 2004年1月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •Women who have given birth to healthy babies
排除标准
- •Does not match inclusion criteria
研究者
相似试验
招募中
1 期
A phase I/II double-blind, randomised controlled trial assessing effect of medicinal cannabis on quality of life and symptom control in advanced cancer.Advanced CancerPalliative CareCancer - Any cancerACTRN12619001534178Olivia Newton-John Cancer Research Institute119
已完成
2 期
A Phase 2 Double -blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of 10 mcg HXP-GPOVac Vaccine in Healthy Volunteershealthy adultsphase 2, covid vaccine, clinical trial, HXP-GPOVacTCTR20220819003Government Pharmaceutical Organization, Thailand300
招募中
2 期
A clinical, randomized study to evaluate the efficacy and safety of Naproxen compared to placebo in combination with Azithromycin or Levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemicSevere acute respiratory syndromeRBR-3rywwgFaculdade de Medicina de São Jose do Rio Preto - FUNFARME/FAMERP
终止
2 期
A phase II, multi-site, double blind, randomised placebo-controlled feasibility trial of crushed oral famotidine for management of Inoperable Malignant Bowel Obstruction (IMBO)Bowel ObstructionMalignant Bowel ObstructionBowel cancerCancer - Bowel - Small bowel (duodenum and ileum)Cancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12621001403820niversity of Technology Sydney4
进行中（未招募）
不适用
An study conducted in multiple countres to assess the control of glucose in patients with Diabetes Type 2. This study will compare 5 different dose levels of HM11260C (the study medication) with placebo (no active drug) and a liraglutide (a treatment for diabetes type 2 available by prescription). This will be a twelve week study where the study physician nor the patient will know whether the treatment is placebo or study medication. There is an equal chance of being assigned to any group.Type 2 Diabetes MellitusEUCTR2013-003625-29-HUHanmi Pharmaceutical Co., Ltd.255